We are live on
!
Find out more
AAP
Ardsley Advisory Partners Portfolio holdings
AUM
$960M
1-Year Est. Return
207.76%
This Fund
S&P 500
This Quarter
Est. Return
+4.4%
1 Year Est. Return
+207.76%
3 Year Est. Return
+554.53%
5 Year Est. Return
+728.66%
10 Year Est. Return
+4,084.52%
AUM
$667M
AUM Growth
-$156M
(-19%)
Cap. Flow
-$137M
Cap. Flow
% of AUM
-20.59%
Top 10 Holdings %
Top 10 Hldgs %
36.65%
Holding
203
New
66
Increased
38
Reduced
28
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ProShares Trust UltraShort Lehman 20+ Year Treasury
TBT
|
+$42.5M |
| 2 |
CELG
Celgene Corp
CELG
|
+$21.6M |
| 3 |
Elevance Health
ELV
|
+$18.4M |
| 4 |
Sunrun
RUN
|
+$13.1M |
| 5 |
Ashland
ASH
|
+$9.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$20.1M |
| 2 |
NSM
Nationstar Mortgage Holdings
NSM
|
+$11.6M |
| 3 |
Macerich
MAC
|
+$11.6M |
| 4 |
NGD
New Gold Inc
NGD
|
+$10.4M |
| 5 |
Hannon Armstrong Sustainable Infrastructure Capital
HASI
|
+$9.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.12% |
| 2 | Technology | 20.78% |
| 3 | Utilities | 7.87% |
| 4 | Industrials | 5.38% |
| 5 | Materials | 4.47% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BOLD
126
DELISTED
Audentes Therapeutics, Inc
BOLD
| $302K | 0.05% |
10,072
-5,000
| -33% | -$169K |
|
|
NVTR
127
DELISTED
Nuvectra Corporation Common Stock
NVTR
| $288K | 0.04% |
22,095
| – | – |
|
128
Rocket Pharmaceuticals
RCKT
$343M
| $281K | 0.04% |
+15,000
| New | +$245K |
|
|
TWTR
129
CALL
DELISTED
Twitter, Inc.
TWTR
| $270K | 0.04% |
+9,300
| New | +$273K |
|
|
GRDX
130
GridAI Technologies Corp
GRDX
$21M
| $259K | 0.04% |
1
| – | – |
|
131
Hasbro
HAS
$13.6B
| $253K | 0.04% |
+3,000
| New | +$278K |
|
|
APEN
132
DELISTED
Apollo Endosurgery, Inc.
APEN
| $251K | 0.04% |
40,000
+11,200
| +39% | +$70.6K |
|
133
Merck
MRK
$326B
| $245K | 0.04% |
+4,716
| New | +$255K |
|
134
Option Care Health
OPCH
$3.53B
| $245K | 0.04% |
25,000
+2,500
| +11% | +$28.9K |
|
|
JWN
135
DELISTED
Nordstrom
JWN
| $242K | 0.04% |
+5,000
| New | +$249K |
|
136
Regenxbio
RGNX
$615M
| $224K | 0.03% |
7,500
-2,500
| -25% | -$72.8K |
|
137
PepsiCo
PEP
$195B
| $218K | 0.03% |
+2,000
| New | +$227K |
|
138
Arrowhead Research
ARWR
$12.1B
| $144K | 0.02% |
+20,000
| New | +$123K |
|
139
Harrow
HROW
$1.47B
| $124K | 0.02% |
70,000
+20,000
| +40% | +$35.5K |
|
140
Sportsman's Warehouse
SPWH
$45.7M
| $102K | 0.02% |
+25,000
| New | +$124K |
|
|
CVRS
141
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $41K | 0.01% |
+30,000
| New | +$34.8K |
|
|
CFRX
142
DELISTED
ContraFect Corporation
CFRX
| $24K | ﹤0.01% |
19
| – | – |
|
|
143
AbbVie
ABBV
$465B
| – | – |
-207,500
| Closed | -$20.1M |
|
144
Ambarella
AMBA
$3.03B
| – | – |
-4,000
| Closed | -$235K |
|
145
Amazon
AMZN
$2.48T
| – | – |
-15,000
| Closed | -$878K |
|
146
Box
BOX
$4.36B
| – | – |
-317,000
| Closed | -$6.7M |
|
147
CareDx
CDNA
$1.85B
| – | – |
-20,000
| Closed | -$147K |
|
148
Cisco
CSCO
$456B
| – | – |
-18,000
| Closed | -$689K |
|
149
Canadian Solar
CSIQ
$927M
| – | – |
-227,800
| Closed | -$3.84M |
|
150
CVS Health
CVS
$140B
| – | – |
-7,500
| Closed | -$545K |
|
Similar funds
NA
MK
QIM
JVBC
TFP
UWPG
LOAMU
PHS
Ardsley Advisory Partners's Q1 2018 Portfolio in Review
As of Q1 2018, Ardsley Advisory Partners held 203 positions worth $667M, down 19% from $823M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Ardsley Advisory Partners withdrew a net $137M in Q1 2018, closing 61 positions and reducing 28 holdings. Its most notable exit was AbbVie, an estimated $20.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 16% a quarter earlier, followed by Technology and Utilities.
Against the trend, Ardsley Advisory Partners opened a new position in Celgene Corp worth $20M.
- Ardsley Advisory Partners's largest Q1 2018 buy was Celgene Corp: 224,500 shares worth $20M.
- Ardsley Advisory Partners added most to ProShares Trust UltraShort Lehman 20+ Year Treasury in Q1 2018, an estimated $42.5M increase.
- Ardsley Advisory Partners's biggest Q1 2018 reduction was Macerich, cutting an estimated $11.6M.
- Ardsley Advisory Partners fully exited AbbVie in Q1 2018, selling an estimated $20.1M.
- Ardsley Advisory Partners's ten largest holdings make up 37% of its $667M portfolio in Q1 2018.
- Ardsley Advisory Partners opened 66 new positions and closed 61 in Q1 2018.
- Ardsley Advisory Partners's portfolio value fell 19% quarter-over-quarter to $667M.
Based on Ardsley Advisory Partners's 13F filing for Q1 2018, filed 15 May 2018.